Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256189675> ?p ?o ?g. }
- W4256189675 abstract "Background Survival rates have greatly improved as a result of more effective treatments for childhood cancer. Unfortunately, the improved prognosis has been accompanied by the occurrence of late, treatment‐related complications. Liver complications are common during and soon after treatment for childhood cancer. However, among long‐term childhood cancer survivors, the risk of hepatic late adverse effects is largely unknown. To make informed decisions about future cancer treatment and follow‐up policies, it is important to know the risk of, and associated risk factors for, hepatic late adverse effects. This review is an update of a previously published Cochrane review. Objectives To evaluate all the existing evidence on the association between antineoplastic treatment (that is, chemotherapy, radiotherapy involving the liver, surgery involving the liver and BMT) for childhood cancer and hepatic late adverse effects. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2018, Issue 1), MEDLINE (1966 to January 2018) and Embase (1980 to January 2018). In addition, we searched reference lists of relevant articles and scanned the conference proceedings of the International Society of Paediatric Oncology (SIOP) (from 2005 to 2017) and American Society of Pediatric Hematology/Oncology (ASPHO) (from 2013 to 2018) electronically. Selection criteria All studies, except case reports, case series, and studies including fewer than 10 patients that examined the association between antineoplastic treatment for childhood cancer (aged 18 years or less at diagnosis) and hepatic late adverse effects (one year or more after the end of treatment). Data collection and analysis Two review authors independently performed the study selection and 'risk of bias' assessment. The 'risk of bias' assessment was based on earlier checklists for observational studies. For the original version of the review, two review authors independently performed data extraction. For the update of the review, the data extraction was performed by one reviewer and checked by another reviewer. Main results Thirteen new studies were identified for the update of this review. In total, we included 33 cohort studies including 7876 participants investigating hepatic late adverse effects after antineoplastic treatment (especially chemotherapy and radiotherapy) for different types of childhood cancer, both haematological and solid malignancies. All studies had methodological limitations. The prevalence of hepatic late adverse effects, all defined in a biochemical way, varied widely, between 0% and 84.2%. Selecting studies where the outcome of hepatic late adverse effects was well‐defined as alanine aminotransferase (ALT) above the upper limit of normal, indicating cellular liver injury, resulted in eight studies. In this subgroup, the prevalence of hepatic late adverse effects ranged from 5.8% to 52.8%, with median follow‐up durations varying from three to 23 years since cancer diagnosis in studies that reported the median follow‐up duration. A more stringent selection process using the outcome definition of ALT as above twice the upper limit of normal, resulted in five studies, with a prevalence ranging from 0.9% to 44.8%. One study investigated biliary tract injury, defined as gamma‐glutamyltransferase (γGT) above the upper limit of normal and above twice the upper limit of normal and reported a prevalence of 5.3% and 0.9%, respectively. Three studies investigated disturbance in biliary function, defined as bilirubin above the upper limit of normal and reported prevalences ranging from 0% to 8.7%. Two studies showed that treatment with radiotherapy involving the liver (especially after a high percentage of the liver irradiated), higher BMI, and longer follow‐up time or older age at evaluation increased the risk of cellular liver injury in multivariable analyses. In addition, there was some suggestion that busulfan, thioguanine, hepatic surgery, chronic viral hepatitis C, metabolic syndrome, use of statins, non‐Hispanic white ethnicity, and higher alcohol intake (> 14 units per week) increase the risk of cellular liver injury in multivariable analyses. Chronic viral hepatitis was shown to increase the risk of cellular liver injury in six univariable analyses as well. Moreover, one study showed that treatment with radiotherapy involving the liver, higher BMI, higher alcohol intake (> 14 units per week), longer follow‐up time, and older age at cancer diagnosis increased the risk of biliary tract injury in a multivariable analysis. Authors' conclusions The prevalence of hepatic late adverse effects among studies with an adequate outcome definition varied considerably from 1% to 53%. Evidence suggests that radiotherapy involving the liver, higher BMI, chronic viral hepatitis and longer follow‐up time or older age at follow‐up increase the risk of hepatic late adverse effects. In addition, there may be a suggestion that busulfan, thioguanine, hepatic surgery, higher alcohol intake (>14 units per week), metabolic syndrome, use of statins, non‐Hispanic white ethnicity, and older age at cancer diagnosis increase the risk of hepatic late adverse effects. High‐quality studies are needed to evaluate the effects of different therapy doses, time trends, and associated risk factors after antineoplastic treatment for childhood cancer." @default.
- W4256189675 created "2022-05-12" @default.
- W4256189675 creator A5000811467 @default.
- W4256189675 creator A5009940462 @default.
- W4256189675 creator A5012660870 @default.
- W4256189675 creator A5018512393 @default.
- W4256189675 creator A5021147501 @default.
- W4256189675 creator A5029704913 @default.
- W4256189675 creator A5036356438 @default.
- W4256189675 creator A5044874720 @default.
- W4256189675 creator A5051410187 @default.
- W4256189675 creator A5052340947 @default.
- W4256189675 creator A5070828788 @default.
- W4256189675 creator A5072911500 @default.
- W4256189675 creator A5074947199 @default.
- W4256189675 date "2019-04-15" @default.
- W4256189675 modified "2023-10-18" @default.
- W4256189675 title "Hepatic late adverse effects after antineoplastic treatment for childhood cancer" @default.
- W4256189675 cites W108852219 @default.
- W4256189675 cites W1173735390 @default.
- W4256189675 cites W1500959943 @default.
- W4256189675 cites W152928116 @default.
- W4256189675 cites W153370275 @default.
- W4256189675 cites W1538971023 @default.
- W4256189675 cites W1556481499 @default.
- W4256189675 cites W155781577 @default.
- W4256189675 cites W1563016534 @default.
- W4256189675 cites W1569751617 @default.
- W4256189675 cites W1575533059 @default.
- W4256189675 cites W163249226 @default.
- W4256189675 cites W172874805 @default.
- W4256189675 cites W17474332 @default.
- W4256189675 cites W1780831116 @default.
- W4256189675 cites W1849000657 @default.
- W4256189675 cites W1911870963 @default.
- W4256189675 cites W19311468 @default.
- W4256189675 cites W1941509421 @default.
- W4256189675 cites W1945172760 @default.
- W4256189675 cites W1961900696 @default.
- W4256189675 cites W1967246357 @default.
- W4256189675 cites W1967271516 @default.
- W4256189675 cites W1967525111 @default.
- W4256189675 cites W1967650967 @default.
- W4256189675 cites W1968099122 @default.
- W4256189675 cites W1969132305 @default.
- W4256189675 cites W1971429922 @default.
- W4256189675 cites W1971944438 @default.
- W4256189675 cites W1975774257 @default.
- W4256189675 cites W1977235641 @default.
- W4256189675 cites W1977934288 @default.
- W4256189675 cites W1978937087 @default.
- W4256189675 cites W1979156036 @default.
- W4256189675 cites W1979515666 @default.
- W4256189675 cites W1979578577 @default.
- W4256189675 cites W1979730678 @default.
- W4256189675 cites W1980952494 @default.
- W4256189675 cites W198234509 @default.
- W4256189675 cites W1983261202 @default.
- W4256189675 cites W1983288890 @default.
- W4256189675 cites W1984052365 @default.
- W4256189675 cites W1984570865 @default.
- W4256189675 cites W1985093410 @default.
- W4256189675 cites W1986253119 @default.
- W4256189675 cites W1986433790 @default.
- W4256189675 cites W1987499970 @default.
- W4256189675 cites W1988582665 @default.
- W4256189675 cites W1989291897 @default.
- W4256189675 cites W1990180383 @default.
- W4256189675 cites W1991257700 @default.
- W4256189675 cites W1991537949 @default.
- W4256189675 cites W1993179567 @default.
- W4256189675 cites W1993638588 @default.
- W4256189675 cites W1993921185 @default.
- W4256189675 cites W1994426303 @default.
- W4256189675 cites W1995176938 @default.
- W4256189675 cites W1995507674 @default.
- W4256189675 cites W1995862451 @default.
- W4256189675 cites W1996234905 @default.
- W4256189675 cites W1998787766 @default.
- W4256189675 cites W1999859736 @default.
- W4256189675 cites W2001008306 @default.
- W4256189675 cites W2003154554 @default.
- W4256189675 cites W2003659648 @default.
- W4256189675 cites W2004216169 @default.
- W4256189675 cites W2005091237 @default.
- W4256189675 cites W2005575131 @default.
- W4256189675 cites W2007765135 @default.
- W4256189675 cites W2008828893 @default.
- W4256189675 cites W2010819955 @default.
- W4256189675 cites W2012246972 @default.
- W4256189675 cites W2013595615 @default.
- W4256189675 cites W2014432477 @default.
- W4256189675 cites W2015532654 @default.
- W4256189675 cites W2015668249 @default.
- W4256189675 cites W2015758016 @default.
- W4256189675 cites W2017538581 @default.
- W4256189675 cites W2018957420 @default.
- W4256189675 cites W2019583063 @default.
- W4256189675 cites W2020940343 @default.
- W4256189675 cites W2020974852 @default.